nasdaq trading, page-15

I'll be peeved if they do issue more shares Skint. I also want to see Prana with a much stronger cash position but by issuing shares at lower prices relative to likely much higher prices post successful trial results they are diluting the upside. Assuming managment can do two things at once why can't they raise funds post results while also progressing?

The only reason to raise cash at this time is to guard against unsuccessful trial results, as you hint with the comment that 'all small biotechs with strong cash positions don't give back gains so easily'. In effect they are giving up some of the upside to protect the downside. I'd rather take the risk.